Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.52 |
| ▸ | PDE5A | O76074 | 8/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | BUB1 | O43683 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883538 | 0.92 | PDE5A (0.53) | ELANEPDE5AADORA3KCNH2BUB1 | |
| SCHEMBL6224401 | 0.84 | PDE5A (0.47) | PDE5AADORA3KCNH2 | |
| SCHEMBL6068600 | 0.84 | CFD (0.49) | PDE5AADORA3KCNH2ATM | |
| SCHEMBL6068675 | 0.83 | PTGDR2 (0.53) | ELANEALDH1A1GAA | |
| SCHEMBL20140289 | 0.82 | ADORA3 (0.45) | PDE5AADORA3KCNH2ATM | |
| Acetic Acid SCHEMBL16245022 | 0.80 | ADORA3 (0.45) | PDE5AADORA3KCNH2ATM | |
| SCHEMBL1217408 | 0.80 | L3MBTL1 (0.61) | ELANEBRD4MEN1ALDH1A1KMT2A | |
| SCHEMBL6223849 | 0.79 | ADORA3 (0.42) | PDE5AADORA3KCNH2ATM | |
| Hydrochloric Acid SCHEMBL6068508 | 0.78 | ADORA3 (0.42) | PDE5AADORA3KCNH2ATM | |
| SCHEMBL8221670 | 0.78 | PDE5A (0.40) | PDE5AADORA3KCNH2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135474-B2 | Derivatives of 2-(1-benzyl-1H-pyrazolo(3,4-B)pyridine-3-yl)-5(-4-pyridinyl)l-4-pyrimidinamines and the use thereof as quanylate cyclase stimulators | BAYER HEALTHCARE AG (DE) | 2006-11-14 | — | — | US | disclosed |
| US-20050222170-A1 | Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)- 5(-4-pyridiny)l-4- pyrimidinamines and the use thereof as quanylate cyclase stimulators | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222170-A1 | Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)- 5(-4-pyridiny)l-4- pyrimidinamines and the use thereof as quanylate cyclase stimulators | PDE3B, PDE5A, PDE3A | ELANE 3837/4885PDE5A 2/4885ADORA3 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.